Effect of valproate on the plasma concentrations of aripiprazole in bipolar patients

Basit Öğe Kaydı
dc.authorid0000-0002-2514-5682en_US
dc.contributor.authorEryilmaz, Gul
dc.contributor.authorSayar, Gokben Hizli
dc.contributor.authorOzten, Eylem
dc.contributor.authorGul, Isil Gogcegoz
dc.contributor.authorKaramustafalioglu, Oguz
dc.contributor.authorYorbik, Ozgur
dc.date.accessioned2024-07-12T21:49:53Z
dc.date.available2024-07-12T21:49:53Z
dc.date.issued2014en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractObjective. There is very limited documentation available on the effects of valproate co-medication on the pharmacokinetics of aripiprazole in a naturalistic setting. The aim of the present study was to investigate the effect of co-medication with valproate on serum concentrations of aripiprazole in bipolar disorder patients in a clinical setting. Method. Plasma samples of bipolar disorder patients (n = 69) on a stable dose of aripiprazole 20 mg/day were analyzed by a liquid chromatography-mass spectrometry method in a routine therapeutic drug monitoring setting. Therapeutic drug monitoring was done for the entire study group before and aft er valproate co-administration. Results. We observed a statistically significant difference between the aripiprazole monotherapy and aripiprazole-valproate combination with respect to total aripiprazole plasma levels (p < 0.01). However, no statistically significant differences were noted in aripiprazole levels between the first week and the second week of valproate co-administration. Conclusion. In conclusion, concurrent treatment with valproate resulted in changes in the total aripiprazole plasma levels by 23%. But a lower total aripiprazole concentration during co-medication with valproate, caused by protein binding displacement, is reported being clinically insignificant in previous studies. The results from these studies are important in order to clarify clinical safety and efficacy.en_US
dc.identifier.doi10.3109/13651501.2014.941879
dc.identifier.endpage292en_US
dc.identifier.issn1365-1501
dc.identifier.issn1471-1788
dc.identifier.issue4en_US
dc.identifier.pmid25000175en_US
dc.identifier.scopus2-s2.0-84910028296en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage288en_US
dc.identifier.urihttps://dx.doi.org/10.3109/13651501.2014.941879
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8103
dc.identifier.volume18en_US
dc.identifier.wosWOS:000344473900011en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherINFORMA HEALTHCAREen_US
dc.relation.ispartofINTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY01303
dc.subjectAripiprazoleen_US
dc.subjectdrug interactionen_US
dc.subjectvalproateen_US
dc.titleEffect of valproate on the plasma concentrations of aripiprazole in bipolar patientsen_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu